We read with interest the article by Newby et al 1 regarding adherence to evidence-based secondary prevention therapies in patients with heart disease. This is an important and sobering study, highlighting the need for better use of proven therapies for patients with coronary artery disease and heart failure. We were surprised, however, at the low rate of adherence to the use of angiotensin-converting enzyme inhibitors (ACEIs) in patients with heart failure. We feel that this reported rate may be somewhat misleading. To obtain information on heart failure drug use, the database was searched for any patient "with an ejection fraction less than 40% or clinical history congestive heart failure." Using that definition, adherence rates to ACEIs were reported as low as 51%. However, up to 50% of patients with evidence of clinical heart failure have preserved systolic function. 2 There is no evidence that ACEIs mitigate the morbidity or mortality from heart failure in patients with preserved systolic function. The American College of Cardiology/American Heart Association guidelines accordingly list ACEIs as a Class IIB agent in patients with heart failure and normal systolic function. 3 In a large survey of patients hospitalized with heart failure, 62% were discharged on an ACEI. 4 However, when this group was assessed according to ejection fraction, 80% of those with an ejection fraction Ͻ40% were discharged on an ACEI. Therefore, we propose that had the authors 1 included only patients with an ejection fractionϽ40% (a Class I recommendation of ACEIs), adherence rates would have been higher.
